User menu

Body weight and fat mass index as strong predictors of factor VIII in vivo recovery in adults with hemophilia A

Bibliographic reference Henrard, Séverine ; Speybroeck, Niko ; Hermans, Cédric. Body weight and fat mass index as strong predictors of factor VIII in vivo recovery in adults with hemophilia A. In: Journal of Thrombosis and Haemostasis, Vol. 10, no. 1, p. 165-166 (2011)
Permanent URL
  1. Bolton-Maggs Paula HB, Pasi K John, Haemophilias A and B, 10.1016/s0140-6736(03)13405-8
  2. Ingram G. I. C., CALCULATING THE DOSE OF FACTOR VIII IN THE MANAGEMENT OF HAEMOPHILIA, 10.1111/j.1365-2141.1981.tb02722.x
  3. Rizza, Human Blood Coagulation, Haemostasis and Thrombosis, 374 (1976)
  4. Saegerman C., Speybroeck N., Roels S., Vanopdenbosch E., Thiry E., Berkvens D., Decision Support Tools for Clinical Diagnosis of Disease in Cows with Suspected Bovine Spongiform Encephalopathy, 10.1128/jcm.42.1.172-178.2004
  5. Aygören-Pürsün, Thromb Haemost, 78, 1352 (1997)
  6. COLLINS P. W., BJÖRKMAN S., FISCHER K., BLANCHETTE V., OH M., SCHROTH P., FRITSCH S., CASEY K., SPOTTS G., EWENSTEIN B. M., Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens, 10.1111/j.1538-7836.2009.03703.x
  7. Morfini M., Cinotti S., Bellatreccia A., Paladino E., Gringeri A., Mannucci P. M., , A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards, 10.1046/j.1538-7836.2003.00481.x
  8. SEREMETIS, LUSHER, ABILDGAARD, KASPER, ALLRED, HURST, , Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy, 10.1046/j.1365-2516.1999.00191.x
  9. Tarantino M. D., Collins P. W., Hay C. R. M., Shapiro A.D., Gruppo R. A., Berntorp E., Bray G. L., Tonetta S. A., Schroth P. C., Retzios A. D., Rogy S. S., Sensel M. G., Ewenstein B. M., , Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A1, 10.1111/j.1365-2516.2004.00932.x
  10. White, Thomb Haemost, 77, 660 (1997)
  11. Abshire, Thromb Haemost, 83, 811 (2000)
  12. BJÖRKMAN S., BLANCHETTE V. S., FISCHER K., OH M., SPOTTS G., SCHROTH P., FRITSCH S., PATRONE L., EWENSTEIN B. M., COLLINS P. W., , Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring, 10.1111/j.1538-7836.2010.03757.x
  13. LAMBERT T., GUÉROIS C., GAY V., STIELTJES N., BERTRAND M.-A., DERLON A., SIGAUD M., HASSOUN A., NÉGRIER C., COATMELEC B., DREYFUS M., DUBANCHET A., Factor VIII recovery after a single infusion of recalibrated ReFacto�in 14 severe haemophilia A patients, 10.1111/j.1365-2516.2007.01482.x
  14. SHI J., ZHAO Y., WU J., SUN J., WANG L., YANG R., Safety and efficacy of a sucrose-formulated recombinant factor VIII product for the treatment of previously treated patients with haemophilia A in China, 10.1111/j.1365-2516.2007.01472.x
  15. Yoshioka A., Shima M., Fukutake K., Takamatsu J., Shirahata A., , Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII-FS) in patients with haemophilia A: a long-term, multicentre clinical study in Japan, 10.1046/j.1365-2516.2001.00511.x
  16. BARNES C., LILLICRAP D., PAZMINO-CANIZARES J., BLANCHETTE V. S., STAIN A. M., CLARK D., HENSMEN C., CARCAO M., Pharmacokinetics of recombinant factor VIII (Kogenate-FS�) in children and causes of inter-patient pharmacokinetic variability, 10.1111/j.1365-2516.2006.01333.x
  17. BLANCHETTE V. S., SHAPIRO A. D., LIESNER R. J., HERNNDEZ NAVARRO F., WARRIER I., SCHROTH P. C., SPOTTS G., EWENSTEIN B. M., , Plasma and albumin-free recombinant factorVIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients, 10.1111/j.1538-7836.2008.03032.x
  18. DI PAOLA J., SMITH M. P., KLAMROTH R., MANNUCCI P. M., KOLLMER C., FEINGOLD J., KESSLER C., POLLMANN H., MORFINI M., UDATA C., ROTHSCHILD C., HERMANS C., JANCO R., ReFacto®1and Advate®2: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A : REFACTO AND ADVATE ARE BIOEQUIVALENT, 10.1111/j.1365-2516.2006.01420.x
  19. Kessler C. M., Gill J. C., White G. C., Shapiro A., Arkin S., Roth D. A., Meng X., Lusher J. M., B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study, 10.1111/j.1365-2516.2005.01068.x
  20. SANTORO C., IORIO A., FERRANTE F., PALLOTTA A., PIGNOLONI P., BIONDO F., AGNELLI G., MAZZUCCONI M. G., Performance of recalibrated ReFacto®laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto®(B-domain deleted recombinant factor VIII), 10.1111/j.1365-2516.2009.01983.x
  21. Aronstam A, McLellan D S, Wassef M, Mbatha P S, Effect of height and weight on the in vivo recovery of transfused factor VIII C., 10.1136/jcp.35.3.289
  22. Bj??rkman Sven, Berntorp Erik, Pharmacokinetics of Coagulation Factors : Clinical Relevance for Patients with Haemophilia, 10.2165/00003088-200140110-00003
  23. COLLINS P. W., FISCHER K., MORFINI M., BLANCHETTE V. S., BJÖRKMAN S., , Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia : PHARMACOKINETICS AND PROPHYLAXIS, 10.1111/j.1365-2516.2010.02370.x
  24. Bjorkman S., Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective, 10.1046/j.1365-2516.9.s1.4.x
  25. Majumdar, Haemophilia, 16, 455 (2010)
  26. HOFSTEDE F. G., FIJNVANDRAAT K., PLUG I., KAMPHUISEN P. W., ROSENDAAL F. R., PETERS M., Obesity: a new disaster for haemophilic patients? A nationwide survey, 10.1111/j.1365-2516.2008.01806.x
  27. Berntorp E., Bjorkman S., The pharmacokinetics of clotting factor therapy, 10.1046/j.1365-2516.2003.00762.x